Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.65 |
| ▸ | PNP | P00491 | 5/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | HPRT1 | P00492 | 9/20 | 0.54 |
| ▸ | TK1 | P04183 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | VCP | P55072 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Penciclovir Triphosphate SCHEMBL30945294 | 1.00 | POLG (0.65) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL7196190 | 0.91 | HPRT1 (0.58) | POLGPNPPOLBPOLA1HPRT1 | |
| Ammonia Solution, Strong SCHEMBL5930250 | 0.91 | HPRT1 (0.57) | POLGPNPPOLBPOLA1HPRT1 | |
| Ammonia Solution, Strong SCHEMBL7750989 | 0.90 | POLG (0.66) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL12800326 | 0.89 | HPRT1 (0.57) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL12732295 | 0.88 | HPRT1 (0.57) | PNPPOLBHPRT1TK1MEN1 | |
| SCHEMBL15630250 | 0.87 | POLG (0.65) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL571368 | 0.87 | POLG (0.65) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL9824169 | 0.87 | HPRT1 (0.60) | PNPHPRT1TK1MEN1ALDH1A1 | |
| SCHEMBL15340416 | 0.86 | HPRT1 (0.55) | POLGPNPPOLBPOLA1HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281470-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20110092458-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-04-21 | — | — | US | disclosed |
| US-7045525-B1 | Use of (R)-peniciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| US-20060069108-A1 | Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | NOVARTIS PHARMACEUTICALS CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-0822817-B1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | NOVARTIS INT PHARM LTD (BM) | 2003-07-23 | — | — | EP | disclosed |
| EP-0822817-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1998-02-11 | — | — | EP | disclosed |
| WO-1996033720-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092458-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | TYMP, PNP, HPRT1 | POLG 96/4885PNP 2/4885POLB 57/4885 |
| US-20130281470-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | TYMP, PNP, HPRT1 | POLG 96/4885PNP 2/4885POLB 57/4885 |
| US-20060069108-A1 | Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | TYMP, PNP, HPRT1 | POLG 96/4885PNP 2/4885POLB 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.